BChE
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a cholinesterase family enzyme that hydrolyzes a broad range of choline esters and other ester-containing substrates, contributing to cholinergic regulation as well as xenobiotic detoxification processes[1][2]. BChE is widely distributed in human tissues and plasma, where it participates in cholinergic transmission, ester metabolism, and the neutralization of toxic compounds including organophosphates and carbamates[1]. Mechanistically, BChE functions as a hydrolytic enzyme that can buffer acetylcholine metabolism when acetylcholinesterase (AChE) activity is reduced, thereby influencing cholinergic homeostasis[2]. In disease contexts, increasing evidence links BChE to neurodegenerative disorders, particularly Alzheimer’s disease (AD), where BChE activity and expression become more prominent during disease progression and are associated with late-stage cholinergic dysfunction[3][4]. Experimental studies therefore consider BChE an important therapeutic target and biomarker candidate for AD-related research[3][4]. Compared with the closely related isoform AChE, which primarily terminates synaptic acetylcholine signaling, BChE exhibits broader substrate specificity, distinct tissue distribution, and a stronger role in drug metabolism, detoxification, and non-neuronal physiological processes[1][2]. For experimental applications, selective BChE inhibitors are widely used to investigate cholinergic mechanisms and have been developed as pharmacological tools for evaluating therapeutic strategies in neurodegenerative disease models, with high selectivity over AChE considered a key design objective[3][4].
References:
- [1]. Hajimohammadi S, et al. New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions. Front Mol Biosci. 2025 Jun 19;12:1625318. [Content Brief]
- [2]. Jovičić SM. Enzyme ChE, et al. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241289013. [Content Brief]
- [3]. Brus B, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2014 Oct 9;57(19):8167-79. [Content Brief]
- [4]. Zhou Y, et al. Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules. 2019 Nov 20;24(23):4217. [Content Brief]
All Product Categories
-
BChE Related Products (229)
Related Products (229)
-
AChE-IN-51
0 ImagesCat. No.: HY-157382AChE-IN-51 (compound 8C) is an orally active, non-competitive inhibitor of AChE and BChE (IC50: 84 nM, 97 nM). It also inhibits MMP-2 and amyloid Aβ1-42 aggregates (IC50: 724 nM, 302 nM). AChE-IN-51 has low cytotoxicity and in silico predicted blood-brain barrier permeability. Can be used for research on diseases such as Alzheimer's disease (AD).
-
BChE-IN-49
0 ImagesCat. No.: HY-181248BChE-IN-49 is an orally active BChE inhibitor with IC50 values of 0.73 μM and 6.43 μM against BChE and AChE, respectively. BChE-IN-49 reduces AChE levels to inhibit the degradation of acetylcholine. By inhibiting GSK-3β, BChE-IN-49 potently activates the Wnt/β-catenin signaling pathway, exerting potent anti-Aβ, antioxidant, anti-neuroinflammatory and anti-apoptotic effects. BChE-IN-49 can be used in research related to Alzheimer's disease.
-
AChE/BChE-IN-38
0 ImagesCat. No.: HY-189414AChE/BChE-IN-38 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC50 = 1.22 μM and 0.40 μM; Ki = 0.94 μM and 0.60 μM). AChE/BChE-IN-38 decreases BACE1 and HTR6 mRNA expression in neuroblastoma cells. AChE/BChE-IN-38 improves cognitive and behavioral parameters in a Scopolamine-induced Alzheimer's disease zebrafish model. AChE/BChE-IN-38 is useful for research on Alzheimer's disease.
-
AChE/BuChE/MAO-B-IN-1
0 ImagesCat. No.: HY-151562CAS No.: 2834758-29-9AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC50s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ1 and σ2 receptors with Ki values of 42.8 nM (human σ1 receptor) and 191 nM (rat σ2 receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research.
-
S27-1047
0 ImagesCat. No.: HY-184583CAS No.: 3121876-09-0S27-1047 is a brain-penetrant, potent and selective BChE (eqBChE IC50 = 7.16 nM; hBChE IC50 = 296.10 nM) inhibitor and Nrf2 activator. S27-1047 can directly bind Keap1, disrupt Keap1-Nrf2 interaction (FP IC50 = 36.87 nM), enhance antioxidant enzyme expression and activate the GSH-GPX4 axis to inhibit Aβ-induced ferroptosis. S27-1047 can protect against oxidative stress and neuroinflammation. S27-1047 can be used in Alzheimer's disease research.
-
CL-13
0 ImagesCat. No.: HY-168301CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC50 of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC50 = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine (HY-N0296) without affecting the mice's motor skills.
-
AChE/BuChE-IN-3
0 ImagesCat. No.: HY-147939CAS No.: 2742707-47-5AChE/BuChE-IN-3 is a potent and blood-brain barrier (BBB) penetrant AChE and BuChE dual inhibitor with IC50s of 0.65 μM and 5.77 μM for AChE and BuChE. AChE/BuChE-IN-3 also inhibits Aβ1-42 aggregation. AChE/BuChE-IN-3 has effectively neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE/BuChE-IN-3 can be used for researching Alzheimer's disease.
-
AChE/BChE-IN-24
0 ImagesCat. No.: HY-159880CAS No.: 3053509-06-8AChE/BChE-IN-24 (compound 5k) is a neuroprotective agent through cholinesterase inhibition. AChE/BChE-IN-24 inhibits AChE and BChE with IC50 values of 16.38 μM and 10.44 μM, respectively.
-
hAChE-IN-8
0 ImagesCat. No.: HY-163514hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research.
-
Lakoochin C
0 ImagesCat. No.: HY-N17425CAS No.: 2170152-91-5Lakoochin C is an inhibitor of acetylcholinesterase (AChE) (IC50 = 61.86 μM) and butyrylcholinesterase (BChE) (IC50 = 47.21 μM). Lakoochin C may be used in research related to Alzheimer's disease.
-
eeAChE-IN-3
0 ImagesCat. No.: HY-162681eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research.
-
BChE-IN-26
0 ImagesCat. No.: HY-161156BChE-IN-26 (Compound 7b) is a selective AChE and BChE inhibitor with Ki value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease.
-
α-Glucosidase-IN-68
0 ImagesCat. No.: HY-162639CAS No.: 1624628-01-8α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models.
-
TRV-7019
0 ImagesCat. No.: HY-153432CAS No.: 2598164-15-7TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity.
-
2-Methyl-2-butenyl (E)-Caffeate
0 ImagesCat. No.: HY-W746884CAS No.: 118971-61-22-Methyl-2-butenyl (E)-Caffeate is a type of caffeic acid ester compound. The petroleum ether and chloroform extracts containing 2-Methyl-2-butenyl (E)-Caffeate have inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The ether extract containing 2-Methyl-2-butenyl (E)-Caffeate exhibits strong antioxidant properties. 2-Methyl-2-butenyl (E)-Caffeate can be used in the research of Alzheimer's disease.
-
AChE-IN-21
0 ImagesCat. No.: HY-150545CAS No.: 2413656-04-7AChE-IN-21 (Compound I-8) is a potent, selective and orally active AChE inhibitor with an IC50 of 2.66 nM. AChE-IN-21 displays excellent BBB permeability in vitro.
-
AChE/BChE-IN-26
0 ImagesCat. No.: HY-173152AChE/BChE-IN-26 (Compound 20aa) is a cholinesterase inhibitor with IC50 values of 0.75 μM and 4.11 μM against eeAChE and eqBChE, respectively. AChE/BChE-IN-26 has antioxidant activity and can be used in the research of diseases such as Alzheimer's disease.
-
AChE/BuChE-IN-6
0 ImagesCat. No.: HY-170561CAS No.: 3105110-19-5AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease.
